News | December 20, 2007

High-Risk Plaque Study Targets Heart Attack, Stroke Patients Prior to Occurrence

December 21, 2007 - BG Medicine, on behalf of the HRP Initiative, today announced the launch of the BioImage Study, designed to discover new blood tests and to optimize non-invasive imaging of atherosclerosis in order to identify and characterize individuals that are at high-risk for coronary heart disease or stroke.

The BioImage Study is the next phase of the High-Risk Plaque Initiative, an industry-funded joint research and development effort to advance the understanding, recognition and management of high-risk plaque (HRP), the primary underlying cause of heart attacks and the leading cause of death in the Western world.

The next phase of the High-Risk Plaque Initiative will leverage advances in diagnostic imaging and blood biomarker science to reduce morbidity, mortality and cost associated with cardiovascular disease

The current method of reducing cardiovascular disease relies on minimizing risk factors, an effective strategy to some degree, however, insufficient for treating established but asymptomatic disease such as HRP. Although the pharmaceutical industry has discovered promising treatment options to reduce the risk of heart attack or stroke associated with HRP, the therapeutic potential of these drugs is compromised by a general inability to identify the people who would benefit most from them. The BioImage Study is designed to identify those individuals with undetected but high-risk
atherosclerosis in the months or years before a heart attack or stroke occurs, by taking advantage of the latest technologies in biomedical imaging and molecular medicine. This approach integrates a set of clinical measurements that may reliably and reproducibly predict those who are most at risk of heart attack or stroke associated with HRP, who would benefit from innovative therapies.

“The BioImage Study is expected to answer many important questions that would help us devise strategies to markedly reduce the burden of cardiovascular disease,” said Valentin Fuster, M.D., Ph.D., a leading international cardiologist and chairman of the Scientific Advisory Board for the HRP Initiative and principal investigator of the BioImage Study. “The collaboration between academia, diagnostic and therapeutic industry participants and a leading health benefit provider creates an unprecedented opportunity to do a different kind of study to search for these answers in a way that would otherwise not be possible.” In addition to his work with the HRP Initiative, Dr. Fuster serves as director of the Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée and Henry R. Kravis Center for Cardiovascular Health and Director of Mount Sinai Heart.

Participants in the BioImage Study will have physical measurements taken (e.g., height, weight, blood pressure and waist/hip circumferences) and blood samples drawn for a number of advanced molecular analyses. Many of these participants will also undergo procedures to capture images of
their hearts and cardiovascular systems. Based on this information, the HRP Initiative will work to discover and validate blood biomarkers that correlate with the imaging data, and that are predictive of future heart attack and stroke associated with HRP.

The BioImage Study is novel not only in its design, but also in the collection of collaborative partners who have joined the HRP Initiative to address this critical medical need. Together with BG Medicine, these partners include Merck, AstraZeneca, Philips, and several distinguished members of academia. This initiative was formed with the shared goal to address atherosclerosis and its associated life-threatening consequences of heart attack and stroke. The current group of HRP Partners is seeking additional companies to collaborate in the HRP Initiative.

Humana, one of the largest publicly traded health benefits companies in the U.S., will offer to selected members in Illinois, Kentucky and Southern Florida the opportunity to participate in the BioImage Study. The study uses mobile diagnostic imaging units equipped with Philips magnetic
resonance (MR) and computed tomography (CT) systems. These units will be located at the sites in Illinois, Kentucky and Florida and will seek to enroll a total of 7,300 volunteers. The BioImage Study, which starts this week in Chicago and is expected to end in December 2008 in Florida, willenroll males age 55-80 and females age 60-80.

For more information: www.bg-medicine.com

Related Content

3D printing of the heart and coronary artery tree from a patient's CT scan.
Sponsored Content | Webinar | 3-D Printing| August 09, 2017
Learn how 3-D printing empowers medical device manufacturer Medtronic to bring products to market faster, develop bet
Moffitt Cancer Center Enhances Patient Care with Toshiba Medical's Infinix-i 4-D
News | Interventional Radiology| August 03, 2017
Cancer patients at Moffitt Cancer Center in Tampa, Fla., now have access to advanced diagnostic imaging for fast and...
Philips released a new version of its iFR system that displays FFR readings as an overlay on live angiographic, angiogram images.

Philips released a new version of its iFR system that displays hemodynamic pressure drop points in an overlay on live angiographic images, matching up the iFR readings with corresponding lesions. The system is supposed to speed diagnostic decision making and help guide percutaneous revascularization procedures. 

Feature | FFR Catheters| July 31, 2017 | Dave Fornell
The gold standard for assessing the hemodynamic significance or coronary lesions to determine if they should be revas
Sponsored Content | Videos | CT Angiography (CTA)| July 21, 2017
DAIC and ITN Editor Dave Fornell discusses some of the most innovative new computed tomography (CT) technology and tr
Cardiac CT scan showing plaque and calcification in the coronary arteries, from a Toshiba CT scanner
News | Business| July 19, 2017
July 19, 2017 — The Society of Cardiovascular Computed Tomography (SCCT) created a reimbursement fee chart for cardia
Sponsored Content | Videos | Cardiac Imaging| July 18, 2017
Leslee Shaw, Ph.D., director of clinical research and professor of medicine at Emory University, Atlanta, and past-pr
Sponsored Content | Videos | CT Angiography (CTA)| July 18, 2017
Matthew Budoff, M.D., FACC, professor of medicine, David Geffen School of Medicine at UCLA, endowed chair of preventi
Sponsored Content | Videos | Business| July 13, 2017
Randall Thompson, M.D., outlines three new CPT codes for FFR-CT, a smart phone-based single-lead ECG system and PET n
FFR-CT, heartflow

An example of an FFR-CT image, showing the FFR values for all coronary vessel segments and the reduction in hemodynamic flow after specific lesions.

News | CT Angiography (CTA)| July 12, 2017
July 12, 2017 — The American Medical Association (AMA) has granted a Category III Tracking Code for estimated coronar
Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve

An example of Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve.

Technology | Computed Tomography (CT)| July 12, 2017
July 12, 2017 — At the 2017 annual meeting for the Society of Cardiovascular Computed Tomography (SCCT), Ziosoft show
Overlay Init